Slide 1: Reaching Patients Through Immunology Innovation
Reaching Patients Through Immunology Innovation 2 Q 2 0 2 5 F I N AN C I AL R E S U LT S C AL L J U LY 3 1 , 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Advancing Vision 2030 with Strong 2Q Financial Results
Advancing Vision 2030 with Strong 2Q Financial Results VISION 2030 ~15K Patients Treated K Patients on Treatment Globally* 3 Phase 3 Assets Labeled Indications 3 New Molecules New Molecules Entered Phase 1 in Phase 3 *Globally ex-China as of June 30, 2025 3
Slide 4: Advancing a Late-Stage Pipeline with Transformative Potential
Advancing a Late-Stage Pipeline with Transformative Potential Efgartigimod Empasiprubart ARGX-119 First and only Potent C2 sweeping MuSK agonist Fc Fragment antibody antibody indications indications indications Ongoing Ongoing Registrational registrational registrational study to start studies studi
Slide 5: Pipeline Growth Driven By Immunology Innovation Program
Pipeline Growth Driven By Immunology Innovation Program Internal External Value Value Creation CLINICAL DISEASE Creation DEVELOPMENT INSIGHT LEO Efgartigimod (ARGX-112) ARGX-119 Leading AbbVie (ARGX-115) ARGX-109 Translational Biology Labs OncoVerity (Cusatuzumab) Empasiprubart Dualyx ARGX-121 ANTIB
Slide 6: Product Net Sales: Q2 of $949 million
Product Net Sales: Q2 of $949 million 949 Product Net Sales by Quarter Q2 2025: growth of 97% vs Q2 2024 (in millions of $) Q2 2025 Q2 2024 Growth % * 790 US 802 407 97% 737 Japan 52 20 138% $’m RoW 83 37 119% 573 China supply 12 14 (10%) Total 949 478 97% 478 398 374 329 269 Q2 2025: growth of 19%
Slide 7: Q2 2025 Financial Summary
Q2 2025 Financial Summary Summary Profit or Loss Three months ended Six months ended Cash* June 30 June 30 $2.1 billion in cash and cash equivalents (in million of $) 2025 2024 2025 2024 and $1.8 billion in current financial assets Product net sales Other operating income 949 19 478 12 1,739 36 876
Slide 8: Delivering Innovation for Patients
Delivering Innovation for Patients For the first time in 8 years I don’t have to plan travel around my hospital schedule, or sacrifice my treatment timing - or my peace of mind – for the needed time away. Lynn, CIDP Patient 8
Slide 9: Strong Launch Fundamentals Driving Expansion
Strong Launch Fundamentals Driving Expansion MG PATIENT GROWTH CIDP PATIENT GROWTH #1 Branded Consistent QoQ Biologic for gMG US New Patient Starts Reaching Patients Earlier Continued Launch Momentum PRESCRIBER EXPANSION BROADEST OFFERING 1K PFS Increased Patient Prescribers 15% new to VYVGART Deman
Slide 10: Growing VYVGART Leadership in MG
Growing VYVGART Leadership in MG Path to 60K Addressable Patients U.S. Addressable MG Patients +25K +7K 60K Growth in Biologics +11K Share of Market Ocular 17K Seronegative PFS Driving Expansion Addressable Total Addressable Market at Launch Market in 2030 Source: argenx market research 10
Slide 11: Delivering Impact for CIDP Patients
Delivering Impact for CIDP Patients 2,500 CIDP Patients treated globally Scott, CIDP Patient 11
Slide 12: Innovation has no meaning unless it provides real benefit to patients
Innovation has no meaning unless it provides real benefit to patients 12
Slide 13: Alternative Performance Measure
Alternative Performance Measure In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for the company’